Bionano Genomics Hosts Day 1 of 2022 Symposium with Six Presentations Highlighting the Superior Performance of OGM in Variant Detection for Constitutional Genetic Diseases
January 10 2022 - 6:26PM
Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping
(OGM) solutions on the Saphyr® system and provider of NxClinical™,
the leading software solutions for visualization, interpretation
and reporting of genomic data, hosted today the first of four days
of 2022 Symposium, the Company’s premiere event showcasing OGM
research applications across key clinical areas of constitutional
genetic disease, hematologic malignancies, solid tumors and OGM
combined with next-generation sequencing (NGS).
Six presentations from leading researchers
across North America and Europe kicked off Symposium.
Today’s event featured six informative speakers from leading
researchers across North America and Europe. These presentations
covered a wide range of constitutional genetic diseases in pre- and
postnatal genetics and offered insight into potential applications
in infertility and reproductive medicine. The presenters supported
OGM as an effective alternative to traditional workflows such as
karyotype, fluorescent in situ hybridization (FISH), chromosomal
microarray (CMA) and Southern blot. Research presentations have
demonstrated greater sensitivity, better resolution and faster
results from OGM workflows compared to traditional methods.
Performance of OGM evaluated in pre- and
postnatal samples. Both Dr. Iqbal from Augusta University
and Dr. Shirley Heggarty compared the performance of OGM in the
evaluation of pre- and postnatal samples with known chromosomal
aberrations. These studies found a high concordance of OGM results
compared to traditional methods. In addition, OGM was able to
identify both unbalanced structural chromosome abnormalities and
balanced structural variants (SVs), like translocations and
inversions, that chromosomal microarray (CMA) could not.
Capabilities of OGM to measure repeat
expansions were evaluated. Dr. Alexander Hoischen
specifically explored the capabilities of OGM to map repeat
expansions, which can be particularly challenging types of SVs, in
subjects with Canvas syndrome and myotonic dystrophy types 1 and 2.
The OGM workflow was able to immediately call very large insertions
with greater precision than the standard cytogenetic techniques and
with 100% concordance. OGM was shown to allow researchers the
ability to see more of the genome, while being less time-consuming
and labor-intensive than other molecular methodologies like
Southern blotting, as Dr. Nikhil Sahajpal discovered. Results from
his validation study were 100% concordant with traditional methods
and demonstrated a streamlined laboratory workflow for different
sample types.
The role of OGM as a discovery tool in
reproductive disorders including infertility. In addition
to pre- and postnatal applications, two speakers, Dr. Laila
El-Khattabi and Chaim Jalas, shared how the OGM workflow plays a
significant role in their research in infertility and reproductive
disorders. In her study, Dr. El-Khattabi used OGM to characterize
apparently balanced SVs related to male infertility and identify
new genes involved in reproductive disorders. Chaim Jalas shared
how OGM used in preimplantation genetic diagnosis can identify
structural rearrangements, including balanced translocations and
inversions, in embryos prior to transfer, which they indicated
could improve pregnancy and delivery rates in an IVF setting.
Among 37 posters appearing in the virtual
exhibition hall the top poster per application area selected to
compete for best poster of Symposium. In addition to the
oral presentations, 37 posters were received and selected for
presentation in the virtual exhibition hall. These posters, in the
virtual exhibition hall, were voted on by attendees of Symposium
and a winner was named in each of four key application areas based
on total number of votes. Below are the four poster winners:
- Constitutional cytogenomics: Dr. Catherine A. Brownstein,
Boston Children’s Hospital
- Hematologic malignancies: Dr. Jonathan L. Lühmann, Hannover
Medical School
- Solid tumors: Dr. Miriam Bornhorst, Children’s National
Hospital
- OGM + NGS: Dr. Nikhil Sahajpal, Augusta University
“Sincere congratulations to our poster winners and
thanks to all poster authors for sharing emerging research on OGM
from their laboratories,” remarked Alka Chaubey, PhD, FACMG, chief
medical officer of Bionano. “This event is made possible with the
enthusiastic participation of the OGM community.”
“We are thrilled at this strong kick-off to the
2022 Symposium and we are excited about the data shared today by
experts from around the world that continues to demonstrate the
utility of OGM workflows in variant detection for constitutional
genetic diseases,” commented Erik Holmlin, PhD, president and
chief executive officer of Bionano. “Congratulations to the poster
winners. We are impressed by all the discoveries our customers are
making with OGM towards the goal of elevating human health.”
Don’t miss Symposium, register
now! Symposium registration is open to all and there is no
charge for attending this event. Register today at
https://www.labroots.com/ms/virtual-event/bngo2022
About Bionano Genomics
Bionano Genomics is a provider of genome analysis
solutions that can enable researchers and clinicians to reveal
answers to challenging questions in biology and medicine. The
Company’s mission is to transform the way the world sees the
genome through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen business,
the Company also provides diagnostic testing for patients with
clinical presentations consistent with autism spectrum disorder and
other neurodevelopmental disabilities. Through its BioDiscovery
business, the Company also offers an industry-leading,
platform-agnostic software solution, which
integrates next-generation sequencing and microarray data
designed to provide analysis, visualization, interpretation and
reporting of copy number variants, single-nucleotide variants and
absence of heterozygosity across the genome in one consolidated
view. For more information, visit www.bionanogenomics.com,
www.lineagen.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano
Genomics
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) convey uncertainty of future events or outcomes
and are intended to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things, the ability for
additional data to support the strength of OGM workflows as
compared to traditional workflows, the ability and utility of OGM
to analyze genomes and reveal answers in genetic disease and cancer
research in less time-consuming and less-labor intensive manners
than traditional workflows, and the potential for OGM to become
part of the standard of care. Each of these forward-looking
statements involves risks and uncertainties. Actual results or
developments may differ materially from those projected or implied
in these forward-looking statements. Factors that may cause such a
difference include the risks and uncertainties associated with: the
impact of the COVID-19 pandemic on our business and the global
economy; general market conditions; changes in the competitive
landscape, including the introduction of competitive technologies
or improvements in existing technologies; failure of future study
results to support those demonstrated during the presentations
referenced in this press release; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts; the ability
of medical and research institutions to obtain funding to support
adoption or continued use of OGM or our technologies; and the risks
and uncertainties associated with our business and financial
condition in general, including the risks and uncertainties
described in our filings with the Securities and Exchange
Commission, including, without limitation, our Annual Report on
Form 10-K for the year ended December 31, 2020 and in other filings
subsequently made by us with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made and are
based on management’s assumptions and estimates as of such date. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of the receipt of
new information, the occurrence of future events or otherwise.
CONTACTSCompany Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com
Investor Relations:Amy ConradJuniper Point+1 (858)
366-3243amy@juniper-point.com
Media Relations:Michael SullivanSeismic+1 (503)
799-7520michael@teamseismic.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Sep 2023 to Sep 2024